Abstract library

16 results for "Ferri".
#2878 Surgical Management of Neuroendocrine Tumor-Associated Liver Metastases
Introduction: Liver metastasis is common among patients who suffer from neuroendocrine tumors (NETs). Radical surgery is the standard treatment whenever possible but there is still controversies concerning the treatment strategies such as resection of the primary, role of debulking surgery, liver transplantation (LT) and neoadjuvant or adjuvant therapies.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Aicha Bengueddach
#2890 Evaluation of Toxicity in Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumors (NET)
Introduction: Peptide receptor radionuclide therapy (PRRT) is an encouraging systemic treatment for neuroendocrine tumors (NET). PRRT is generally safe and possesses little side effects but little is known about liver toxicity.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. Heying Duan
Authors: Duan H, Girod B, Ninatti G, Ferri V, ...
Keywords: NET, PRRT, Toxicity
#2894 Single Institution Experience with Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)
Introduction: Neuroendocrine tumors (NETs) are a rare and heterogenous group of tumors with rising incidence. Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogue is an encouraging systemic treatment modality with minimum side effects.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. Heying Duan
Authors: Duan H, Ninatti G, Girod B, Ferri V, ...
Keywords: NET, PRRT, ORR, PFS
#3043 Angiogenetic Markers as Prognostic Predictors in Neuroendocrine Neoplasms
Introduction: Neoangiogenesis is crucial for NEN development and metastatization.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Giulia Puliani
Authors: Puliani G, Feola T, Sesti F, Sciarra F, ...
Keywords: biomarkers, prognosis
#3044 Efficacy of Alkylating Agent Re-challenge after Therapeutic Pause in Metastatic Pancreatic Neuroendocrine Tumors (PanNET)
Introduction: Temozolomide (TMZ) and dacarbazine (DTIC) are alkylating agents (ALK) with antitumor efficacy in metastatic PanNET. Rechallenging ALK following prior efficacy is commonly performed but has not been evaluated.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Louis de Mestier
#398 Ileal GEP-NEN in Mother and Son – Option for Familial Disease
Introduction: Familial cases of ileal GEP-NEN have been described on some few occasions in the literature. Speculations of familial disease with or without a relationship to MEN-1 or other inherited endocrine neoplasias have been made
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD, PhD Joakim Hennings
#838 Succinate Dehydrogenase Subunit B (SDHB) Immunohistochemistry Should Not Replace Clinical Genetic Testing for SDHx Mutations in Patients with Pheochromocytoma and Paraganglioma
Introduction: Mutations in any of the subunits of the succinate dehydrogenase (SDH) complex predispose to PCC/PGL. Knowing the germline mutation is important for surveillance for recurrence, metastatic disease or more primary tumors and for screening affected family members. Expression of SDHB protein by immunohistochemistry (IHC) has been proposed as a surrogate marker for SDHx mutation status, with absent or decreased expression of SDHB suggesting the presence of a germline SDHB mutation or disruption of the SDH complex by mutation in another subunit.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Lauren Fishbein
#1040 TIM16 Inhibition Decreases Calcitonin Secretion and Enhances Sensitivity to Paclitaxel in a Human Medullary Thyroid Carcinoma Cells
Introduction: TIM 16 protein is part of the traslocase complex TIM 23 situated in the mitochondrial inner membrane, encoded by the Magmas gene, that is overexpressed in several tumors. Magmas silencing causes a greater sensitivity to apoptotic stimuli. We recently demonstrated that, in a human medullary thyroid carcinoma cell line (TT), compound 5, a TIM 16 inhibitor, was not cytotoxic but enhanced the proapoptotic effects of staurosporine
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr Teresa Gagliano
#1101 Malignant Insulinoma in a Patient with Diabetes: Response to Treatment and a Return to Insulin Injections
Introduction: A 64 year old male with a fourteen year history of diabetes had been treated with insulin for eight years. Over a four week period he noticed that his insulin requirements were reducing and he experienced episodes of symptomatic hypoglycaemia and upper abdominal pain. Following referral a CT scan was performed which revealed numerous liver metastases and a 8.4 by 5.2 cm mass replacing the pancreas. Liver biopsy diagnosed a neuroendocrine tumour with a MIB-1 index of up to 18%. The tumour was somatostatin receptor positive as evidenced by an octreotide scan.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Clinical cases/reports
Presenting Author: Dr David Sherriff
Authors: Sherriff D, Drake B, ...
Keywords: insulinoma, diabetes, prrt
#1132 177Lu-Dotatate Re-Treatment in G1-G2 Gastro-Entero-Pancreatic (GEP) NETs
Introduction: PRRT is a valid and well tollerated therapy for G1-G2GEP-NETs. A median PFS of >22 mo. has been reported after PRRT and OS of > 5 years is frequent.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MD Maddalena Sansovini